Sugi Predict

Sugi Predict / Targets / PTCD3

PTCD3

Small ribosomal subunit protein mS39 · Q96EY7 · PTCD3 on Sugi Atlas →

0 patent compounds predicted against PTCD3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PTCD3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma nanCOMPLETED
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Genetics of Primary Ciliary Dyskinesia nanCOMPLETED
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy nanCOMPLETED
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease nanRECRUITING
Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes nanUNKNOWN
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Genetic Study of Patients With Primary Ciliary Dyskinesia nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
Diagnosis of Primary Ciliary Dyskinesia nanCOMPLETED
PCD New Gene Discovery nanCOMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Natural History of Asphyxiating Thoracic Dystrophy (DTJ) nanCOMPLETED
Target of Suv420h1/2 in Hepatocytes nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PTCD3 binder may also engage these)

ProteinNameSimilarity
Q5R8W8 — 1.000 Q5R8W8 →
Q14C51 — 1.000 Q14C51 →
Q32N55 — 1.000 Q32N55 →
Q0IHP3 — 1.000 Q0IHP3 →
Q6PB66 — 1.000 Q6PB66 →
Q32LU7 — 1.000 Q32LU7 →
Q2KI62 — 0.999 Q2KI62 →
Q28C74 — 0.998 Q28C74 →
A1L2L5 — 0.996 A1L2L5 →
A1Z9A8 — 0.995 A1Z9A8 →
Q5SGE0 — 0.994 Q5SGE0 →
Q8WV60 — 0.992 Q8WV60 →
Q08CK1 — 0.991 Q08CK1 →
Q6GQ66 — 0.991 Q6GQ66 →
O15091 — 0.991 O15091 →
Q8VYR5 — 0.990 Q8VYR5 →
Q5SNQ7 — 0.990 Q5SNQ7 →
FASTKD1 FAST kinase domain-containing protein 1, mitochondrial 0.990 landscape →
Q2KI89 — 0.990 Q2KI89 →
LRPPRC Leucine-rich PPR motif-containing protein, mitochondrial 0.990 landscape →
Q8BTZ4 — 0.989 Q8BTZ4 →
B5DF07 — 0.989 B5DF07 →
Q5R629 — 0.989 Q5R629 →
Q9U6M0 — 0.989 Q9U6M0 →
Q5R503 — 0.988 Q5R503 →
Q14CX7 — 0.988 Q14CX7 →
Q3SZ55 — 0.988 Q3SZ55 →
Q7Z3E5 — 0.988 Q7Z3E5 →
Q8BWZ3 — 0.988 Q8BWZ3 →
Q7T163 — 0.988 Q7T163 →